Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2014 (2014), Article ID 141360, 7 pages
http://dx.doi.org/10.1155/2014/141360
Research Article

Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients

1Department of Hematology and Blood Bank,Theodor Bilharz Research Institute, Giza 12411, Egypt, Egypt
2Department of Central Military Laboratory, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi Arabia
3Department of Adult Clinical Hematology and Stem Cell Therapy, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
4Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi Arabia

Received 21 September 2013; Revised 21 December 2013; Accepted 12 January 2014; Published 20 February 2014

Academic Editor: Andreas Neubauer

Copyright © 2014 Ghaleb Elyamany et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Small, M. Levenstein, E. Kim et al., “STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 2, pp. 459–463, 1994. View at Google Scholar · View at Scopus
  2. O. Rosnet, H.-J. Bühring, S. Marchetto et al., “Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells,” Leukemia, vol. 10, no. 2, pp. 238–248, 1996. View at Google Scholar · View at Scopus
  3. D. Gary Gilliland and J. D. Griffin, “The roles of FLT3 in hematopoiesis and leukemia,” Blood, vol. 100, no. 5, pp. 1532–1542, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Markovic, K. L. MacKenzie, and R. B. Lock, “FLT-3: a new focus in the understanding of acute leukemia,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 6, pp. 1168–1172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Kuchenbauer, W. Kern, C. Schoch et al., “Detailed analysis of FLT3 expression levels in acute myeloid leukemia,” Haematologica, vol. 90, no. 12, pp. 1617–1625, 2005. View at Google Scholar · View at Scopus
  6. M. Nakao, S. Yokota, T. Iwai et al., “Internal tandem duplication of the flt3 gene found in acute myeloid leukemia,” Leukemia, vol. 10, no. 12, pp. 1911–1918, 1996. View at Google Scholar · View at Scopus
  7. D. Small, “FLT3 mutations: biology and treatment,” Hematology/the Education Program of the American Society of Hematology, pp. 178–184, 2006. View at Google Scholar · View at Scopus
  8. S. Fröhling, R. F. Schlenk, J. Breitruck et al., “Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm,” Blood, vol. 100, no. 13, pp. 4372–4380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Kiyoi and T. Naoe, “FLT3 mutations in acute myeloid leukemia,” Methods in Molecular Medicine, vol. 125, pp. 189–197, 2006. View at Google Scholar · View at Scopus
  10. L.-Y. Shih, C.-F. Huang, P.-N. Wang et al., “Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia,” Leukemia, vol. 18, no. 3, pp. 466–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Gari, A. Abuzenadah, A. Chaudhary et al., “Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis,” International Journal of Molecular Sciences, vol. 9, no. 11, pp. 2194–2204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ishfaq, A. Malik, M. Faiz et al., “Molecular characterization of FLT3 mutations in acute leukemia patients in Pakistan,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 9, pp. 4581–4585, 2012. View at Publisher · View at Google Scholar
  13. Y. Y. Xu, L. Gao, Y. Ding et al., “Detection and clinical significance of FLT3-ITD gene mutation in patients with acute myeloid leukemia,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 20, no. 6, pp. 1312–1315, 2012. View at Google Scholar
  14. Z. X. Ding, H. J. Shen, J. C. Miao et al., “NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia,” Zhonghua Xue Ye Xue Za Zhi, vol. 33, no. 10, pp. 829–834, 2012. View at Google Scholar
  15. F. Zaker, M. Mohammadzadeh, and M. Mohammadi, “Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes,” Archives of Iranian Medicine, vol. 13, no. 1, pp. 21–25, 2010. View at Google Scholar · View at Scopus
  16. Y. Wang, Z. Li, C. He et al., “MicroRNAs expression signatures are associated with lineage and survival in acute leukemias,” Blood Cells, Molecules, and Diseases, vol. 44, no. 3, pp. 191–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Al-Tonbary, A. K. Mansour, H. Ghazy, D. M. Elghannam, and H. A. Abd-Elghaffar, “Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia,” International Journal of Laboratory Hematology, vol. 31, no. 3, pp. 320–326, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Suzuki, M. Onizuka, M. Kojima et al., “Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population,” International Journal of Hematology, vol. 86, no. 5, pp. 422–428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Wang, D. Lin, X. Zhang, S. Chen, M. Wang, and J. Wang, “Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients,” Leukemia Research, vol. 29, no. 12, pp. 1393–1398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. C. U. Auewarakul, N. Sritana, C. Limwongse, W. Thongnoppakhun, and P.-T. Yenchitsomanus, “Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population,” Cancer Genetics and Cytogenetics, vol. 162, no. 2, pp. 127–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. H. Sheikhha, A. Awan, K. Tobal, and J. A. Liu Yin, “Prognostic significance of FLT3 1TD and D835 mutations in AML patients,” Hematology Journal, vol. 4, no. 1, pp. 41–46, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Thiede, C. Steudel, B. Mohr et al., “Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis,” Blood, vol. 99, no. 12, pp. 4326–4335, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. U. Bacher, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger, “Prognostic relevance of FLT3-TKD mutations in AML: the combination matters an analysis of 3082 patients,” Blood, vol. 111, no. 5, pp. 2527–2537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. J. Mead, D. C. Linch, R. K. Hills, K. Wheatley, A. K. Burnett, and R. E. Gale, “FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia,” Blood, vol. 110, no. 4, pp. 1262–1270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Andersson, B. Johansson, C. Lassen, F. Mitelman, R. Billström, and T. Fioretos, “Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients,” European Journal of Haematology, vol. 72, no. 5, pp. 307–313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. I. Moreno, G. Martin, P. Bolufer et al., “Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia,” Haematologica, vol. 88, no. 1, pp. 19–24, 2003. View at Google Scholar · View at Scopus
  27. F. M. Abu-Duhier, A. C. Goodeve, G. A. Wilson, R. S. Care, I. R. Peake, and J. T. Reilly, “Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia,” British Journal of Haematology, vol. 113, no. 4, pp. 983–988, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Yamamoto, H. Kiyoi, Y. Nakano et al., “Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies,” Blood, vol. 97, no. 8, pp. 2434–2439, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Kiyoi, T. Naoe, Y. Nakano et al., “Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia,” Blood, vol. 93, no. 9, pp. 3074–3080, 1999. View at Google Scholar · View at Scopus
  30. H. Kiyoi, M. Towatari, S. Yokota et al., “Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product,” Leukemia, vol. 12, no. 9, pp. 1333–1337, 1998. View at Google Scholar · View at Scopus
  31. M. Levis and D. Small, “FLT3: ITDoes matter in leukemia,” Leukemia, vol. 17, no. 9, pp. 1738–1752, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. D. L. Stirewalt and J. P. Radich, “The role of FLT3 in haematopoietic malignancies,” Nature Reviews Cancer, vol. 3, no. 9, pp. 650–665, 2003. View at Google Scholar · View at Scopus
  33. S. Meshinchi, W. G. Woods, D. L. Stirewalt et al., “Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia,” Blood, vol. 97, no. 1, pp. 89–94, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. D.-C. Liang, L.-Y. Shih, I.-J. Hung et al., “Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia,” Cancer, vol. 94, no. 12, pp. 3292–3298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Yokota, H. Kiyoi, M. Nakao et al., “Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines,” Leukemia, vol. 11, no. 10, pp. 1605–1609, 1997. View at Google Scholar · View at Scopus
  36. P. Chang, M. Kang, A. Xiao et al., “FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia,” BMC Cancer, vol. 10, article 513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Horiike, S. Yokota, M. Nakao et al., “Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia,” Leukemia, vol. 11, no. 9, pp. 1442–1446, 1997. View at Google Scholar · View at Scopus
  38. E. Ishii, M. Zaitsu, K. Ihara, T. Hara, and S. Miyazaki, “High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells,” Pediatric Hematology and Oncology, vol. 16, no. 5, pp. 437–441, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. P. D. Kottaridis, R. E. Gale, M. E. Frew et al., “The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials,” Blood, vol. 98, no. 6, pp. 1752–1759, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Schnittger, C. Schoch, M. Dugas et al., “Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease,” Blood, vol. 100, no. 1, pp. 59–66, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. S. P. Whitman, K. J. Archer, L. Feng et al., “Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study,” Cancer Research, vol. 61, no. 19, pp. 7233–7239, 2001. View at Google Scholar · View at Scopus
  42. A. Y. H. Leung, C.-H. Man, and Y.-L. Kwong, “FLT3 inhibition: a moving and evolving target in acute myeloid,” Leukemia, vol. 27, pp. 260–268, 2013. View at Publisher · View at Google Scholar
  43. W. Li, L. Zhang, L. Huang, Y. Mi, and J. Wang, “Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML,” Leukemia Research, vol. 36, no. 2, pp. 186–191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Warren, R. Luthra, C. C. Yin et al., “Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients,” Modern Pathology, vol. 25, no. 10, pp. 1405–1412, 2012. View at Publisher · View at Google Scholar